US Patent 11834504 DARPin based multi-specific t-cell engagers
Patent 11834504 was granted and assigned to Molecular Partners on December, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 7 Dec, 2023
Golden AI
Edits made to:
Infobox (+33 properties)
Article (+575 characters)
US Patent 11834504 DARPin based multi-specific t-cell engagers
Article
Patent abstract
The present invention relates to recombinant multi-specific proteins comprising binding agents with binding specificity for different targets, such as, e.g. CD3, CD33, CD123 and CD70. In addition, the invention relates to nucleic acids encoding such multi-specific proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g. acute myeloid leukaemia (AML), in a mammal, including a human.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Bernd Schlereth0
Christian Reichen0
Matteo Bianchi0
Nina Reschke0
Sebastian Grimm0
Victor Levitsky0
Date of Patent
December 5, 2023
0Patent Application Number
176542090
Date Filed
March 9, 2022
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11834504 DARPin based multi-specific t-cell engagers
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
